SCHEDULE 13G/A: Goldman Sachs Divests Entire Stake in Lumos Pharma, Inc.

Sentiment:

Beneficial Ownership Amendment 13 February 2025 9:02 PM

📋All filings for Goldman Sachs Group INC

Goldman Sachs Group and its subsidiary Goldman Sachs & Co. LLC have filed an amended Schedule 13G indicating they no longer hold a beneficial ownership stake in Lumos Pharma, Inc. as of December 31, 2024.

Worse than expectedThe filing indicates that The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC no longer hold any beneficial ownership (0.0%) in Lumos Pharma, Inc., which is a significant reduction from previous holdings and can be interpreted as a negative signal by the market.

Summary

The Goldman Sachs Group, Inc. and its subsidiary, Goldman Sachs & Co. LLC, filed an Amendment No. 2 to Schedule 13G regarding their beneficial ownership of Lumos Pharma, Inc. common stock.
As of December 31, 2024, both reporting entities reported 0.0% beneficial ownership of Lumos Pharma, Inc. common stock.
This filing indicates a complete divestment or reduction below the 5% reporting threshold by Goldman Sachs.

Sentiment

Score: 3

Explanation: The complete divestment of shares by a major institutional investor like Goldman Sachs is generally viewed negatively by the market, as it can signal a lack of confidence or a strategic shift away from the company.

Negatives

Goldman Sachs Group and Goldman Sachs & Co. LLC have reduced their beneficial ownership in Lumos Pharma, Inc. to 0.0%.
The complete divestment by a significant institutional investor like Goldman Sachs could be perceived negatively by the market, potentially signaling a lack of confidence or a shift in investment strategy regarding Lumos Pharma.

Future Outlook

Industry Context

This filing reflects a change in institutional investor holdings within the biotechnology or pharmaceutical sector, where Lumos Pharma operates. Such divestments by major financial institutions can influence market perception and investor sentiment towards companies in the sector, especially smaller-cap firms.

Stakeholder Impact

Shareholders may react negatively to the news of a major institutional investor divesting its entire stake, potentially leading to a decrease in share price.
The company's ability to attract future institutional investment might be impacted if this divestment is perceived as a lack of confidence.

Key Dates

Date	Description
07/29/2024	Date of the Power of Attorney granted by The Goldman Sachs Group, Inc. to its attorneys-in-fact.
10/01/2024	Date of the Power of Attorney granted by Goldman Sachs & Co. LLC to its attorneys-in-fact.
12/31/2024	Date of event requiring the filing of this statement, indicating the beneficial ownership percentage as of this date.
02/11/2025	Date of signing for The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC, and the date of the Joint Filing Agreement.
07/29/2025	Expiration date of the Power of Attorney for The Goldman Sachs Group, Inc.
10/01/2025	Expiration date of the Power of Attorney for Goldman Sachs & Co. LLC.

Recommendation

sell

Keywords

Lumos Pharma, Goldman Sachs, Schedule 13G, Beneficial Ownership, Stock Divestment, Institutional Investor, Common Stock, SEC Filing

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.